Tony Bihl, CEO of Bioventus reported, “Orthobiologics will continue to evolve to meet the needs of patients, surgeons and payers and Bioventus is pleased to begin work on the next generation of bone graft solutions with LifeLink. This approach is consistent with our strategy to grow sales of our existing products in the surgical orthobiologics space and expand our offering with new product innovations.”

“The gift of tissue donation is invaluable and offers the opportunity to benefit so many patients in need,” said Jean Davis, President and CEO of LifeLink Foundation, Inc. “Companies like Bioventus are helping to further enhance the immeasurable impact of tissue donations by investing in R&D to bring new solutions to the market and we are excited for our research teams to collaborate together on this development initiative.”